CTLA4 and colorectal carcinoma: We did not have any patient treated with ICI drugs; however, our molecular data suggested significantly increased expression of CTLA4 and HAVCR2 in only MSI tumors and not in the MSS tumors, suggesting possible beneficial effects of the CTLA4 inhibitor (e.g., ipilimumab) and the HAVCR2 inhibitor in this subgroup of CRC patients.